CA
NZ
UK
AU
IND
US
● The prior range was $350 million to $370 million, so the midpoint rises from $360 million to $415 million.
● Keros will receive a $20 million milestone from Takeda after first patient dosing in the Phase 3 ELRiSE MF trial.
● Lifecore's third amendment with Alcon Research moves the initial term end from December 31, 2031 to December 31, 2034.
● A media report said AbbVie won FDA approval for Juvmo, a once-daily Parkinson's pill, though the date was not confirmed.
● Iovance raised 2026Revenueguidance to $410 million to $420 million from $350 million to $370 million on U.S. demand.
● AstraZeneca agreed to a $2 billion strategicEquityInvestmentin Summit alongside a clinical collaboration on cancer studies.
● uniQure traded near $25 on Tuesday, September 29, 2026, after even steeper declines in premarket trading.
● Vor Bio released a post hoc analysis of Phase 3 telitacicept data in generalized myasthenia gravis on September 29, 2026.
● JPMorgan initiated coverage of AbCellera with an Overweight rating and a $17 price target on Tuesday, September 29, 2026.
● The FDA issued warning letters to Neogen and contract manufacturer Sciarra Aeromed on Tuesday, September 29, 2026.
Please wait processing your request...